ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015
Immunomodulatory antibody therapy of cancer: the closer, the better.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Review
- Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).Annals of oncology : official journal of the European Society for Medical Oncology · 2018Article
- State of play and clinical prospects of antibody gene transfer.Journal of translational medicine · 2017Review
- A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.SOJ immunology · 2017Article
- The Promise of Preventive Cancer Vaccines.Vaccines · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.